Opportunity Information: Apply for PA 18 719
The National Institutes of Health (NIH) funding opportunity titled "Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number PA-18-719) is a discretionary grant program designed to speed up scientific discovery in hidradenitis suppurativa (HS). It uses the NIH R01 research project grant mechanism and sits within the health funding activity category (CFDA 93.846). The overarching goal is to deepen understanding of what causes HS and how it develops at the cellular and molecular levels, then use those insights to move the field toward better ways to control the disease and improve patient outcomes.
The scientific focus is on basic and translational mechanistic research. NIH is looking for projects that investigate HS etiology and disease-driving mechanisms, including environmental influences and a wide range of biological contributors such as genetic and epigenetic factors, immune pathways, and other molecular and cellular processes that may cause HS or be associated with it. The announcement explicitly encourages studies that can clarify how HS begins, what sustains inflammation and tissue damage, and which pathways or targets might be most promising for future therapeutic development. A key theme is pushing knowledge from bench research toward clinical relevance, so projects that connect mechanistic findings to tangible translational applications (for example, identifying actionable pathways, biomarkers, or candidate targets) align well with the intent of the FOA.
In terms of approach, the FOA supports a broad range of mechanistic study designs using both animal and human models. This can include laboratory-based experiments, preclinical model development or refinement, and translational investigations using human-derived samples or systems that help explain disease biology. The announcement emphasizes multidisciplinary collaboration, reflecting NIH interest in bringing together expertise across immunology, genetics, dermatology, microbiology, systems biology, bioinformatics, pathology, and related fields. The idea is that coordinated, cross-disciplinary teams can accelerate the cycle of discovery and enable faster exchange of insights that can ultimately inform therapy development, even if the funded work itself is not testing interventions in patients.
At the same time, the FOA draws clear boundaries around what it will not support. It is not intended for applications that propose epidemiology studies, and it does not support clinical trials (as reflected in the title "Clinical Trial Not Allowed"). In practice, that means applicants should avoid proposing prospective intervention studies in humans that evaluate the efficacy of a treatment or prevention strategy. The emphasis is instead on mechanistic research that builds the foundation for later clinical testing under separate trial-appropriate funding opportunities.
Eligibility is broad and includes many types of organizations that can carry out biomedical research. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than higher education institutions); for-profit organizations other than small businesses; small businesses; and other organizations. The FOA also highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, non-domestic (non-U.S.) entities (foreign organizations), Indian/Native American tribal governments other than federally recognized entities, and U.S. territories or possessions. This broad eligibility is consistent with NIH’s intent to draw on diverse institutions and research environments to move HS science forward.
Administrative details included in the source information indicate the opportunity was created on March 28, 2018, with an original closing date listed as September 7, 2021, and an award ceiling of $500,000. The FOA is structured as a grant funding instrument, and while the provided data do not specify the expected number of awards, the central takeaway is that NIH is committing resources to expand the mechanistic and translational evidence base for HS, prioritizing studies that explain disease drivers and set the stage for future therapeutic strategies without directly running clinical trials or population-level epidemiologic investigations.Apply for PA 18 719
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
- This funding opportunity was created on 2018-03-28.
- Applicants must submit their applications by 2021-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is the National Institutes of Health (NIH) funding announcement titled "Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)" with Funding Opportunity Number PA-18-719. It is a discretionary grant program using the NIH R01 research project grant mechanism.
What disease area does this opportunity focus on?
The focus is hidradenitis suppurativa (HS). The goal is to accelerate scientific discovery that improves understanding of what causes HS and how it develops, with an emphasis on work that can ultimately help improve patient outcomes.
What is the main purpose or goal of the FOA?
The overarching goal is to deepen understanding of HS etiology and pathogenesis at cellular and molecular levels and use those insights to move toward better disease control and improved patient outcomes. The FOA emphasizes building mechanistic knowledge that can inform future therapeutic strategies.
What types of research are encouraged?
The FOA encourages basic and translational mechanistic research. Projects are expected to investigate HS etiology and disease-driving mechanisms, including environmental influences and biological contributors such as genetic factors, epigenetic factors, immune pathways, and other molecular and cellular processes associated with HS.
What does "basic and translational mechanistic research" mean in the context of this FOA?
In this FOA, it refers to studies designed to explain how HS begins, what sustains inflammation and tissue damage, and which molecular/cellular pathways may be driving disease. It also emphasizes connecting mechanistic findings to translational relevance, such as identifying actionable pathways, biomarkers, or candidate targets for future therapeutic development.
What kinds of scientific questions does NIH want applicants to address?
NIH is looking for studies that clarify HS disease initiation, mechanisms that sustain inflammation and tissue damage, and biological pathways or targets that could be promising for later therapeutic development. The FOA also supports investigation of environmental influences and a wide range of biological contributors (genetic, epigenetic, immune, molecular, and cellular).
Are translational applications required?
The FOA strongly emphasizes moving from mechanistic findings toward clinical relevance. Projects that connect bench discoveries to translational applications (for example, identifying biomarkers or actionable pathways/targets) align well with the stated intent, even though the funded work is not meant to test interventions in patients.
What study approaches and models are supported?
The FOA supports a broad range of mechanistic study designs using both animal and human models. This can include laboratory-based experiments, preclinical model development or refinement, and translational investigations using human-derived samples or systems to help explain disease biology.
Does this FOA support research using human-derived samples?
Yes. The FOA explicitly includes translational investigations using human-derived samples or systems, as long as the work is mechanistic and aimed at explaining disease biology rather than testing an intervention as a clinical trial.
Does this FOA support animal model research?
Yes. The FOA supports mechanistic studies using animal models and also supports development or refinement of preclinical models that can help explain HS biology.
Is multidisciplinary collaboration encouraged?
Yes. The FOA emphasizes multidisciplinary collaboration and highlights NIH interest in coordinated, cross-disciplinary teams to accelerate discovery and enable faster exchange of insights.
What fields or disciplines are relevant to this FOA?
The FOA mentions interest in bringing together expertise across areas such as immunology, genetics, dermatology, microbiology, systems biology, bioinformatics, pathology, and related fields.
Are clinical trials allowed under this opportunity?
No. The FOA title includes "Clinical Trial Not Allowed," and the announcement states it does not support clinical trials. Applicants should avoid proposing prospective human intervention studies that evaluate the efficacy of a treatment or prevention strategy.
What does "Clinical Trial Not Allowed" mean for applicants?
It means the application should not propose prospective intervention studies in humans designed to evaluate the efficacy of a treatment or prevention strategy. The FOA is oriented toward mechanistic research that lays groundwork for later clinical testing under other, trial-appropriate opportunities.
Are epidemiology studies supported?
No. The FOA is not intended for applications that propose epidemiology studies.
If clinical trials are not allowed, how does this FOA support progress toward therapies?
The FOA is designed to support foundational mechanistic and translational research that identifies disease drivers, pathways, targets, or biomarkers. Those outputs are intended to set the stage for future therapeutic development and later clinical testing through separate funding opportunities.
What grant mechanism is used for this FOA?
This FOA uses the NIH R01 research project grant mechanism.
What is the funding activity category and CFDA listing?
The opportunity sits within the health funding activity category and is associated with CFDA 93.846.
Who is eligible to apply?
Eligibility is broad and includes many organization types, such as state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than higher education institutions); for-profit organizations other than small businesses; small businesses; and other organizations.
Are minority-serving institutions and other special categories explicitly included as eligible?
Yes. The FOA highlights additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, faith-based or community-based organizations, eligible federal agencies, regional organizations, non-domestic (non-U.S.) entities (foreign organizations), Indian/Native American tribal governments other than federally recognized entities, and U.S. territories or possessions.
Are non-U.S. (foreign) organizations eligible?
Yes. The FOA includes non-domestic (non-U.S.) entities (foreign organizations) among the eligible applicant categories.
Are for-profit organizations eligible?
Yes. The eligible applicants listed include for-profit organizations other than small businesses, as well as small businesses.
What is the award ceiling mentioned in the opportunity details?
The administrative details provided list an award ceiling of $500,000.
When was this opportunity created?
The provided administrative details indicate the opportunity was created on March 28, 2018.
What is the original closing date shown in the provided details?
The source information lists an original closing date of September 7, 2021.
Does the provided information state how many awards NIH expects to make?
No. The provided data do not specify the expected number of awards.
What types of projects would be a poor fit for this FOA based on the stated boundaries?
Applications proposing epidemiology studies or clinical trials (including prospective human intervention studies evaluating treatment or prevention efficacy) would not align with the FOA as described. The intent is mechanistic basic and translational research rather than population-level epidemiology or intervention testing.
What is the central takeaway of NIH's intent for this FOA?
NIH is committing resources to expand the mechanistic and translational evidence base for HS, prioritizing studies that explain disease drivers and support future therapeutic strategies, without directly conducting clinical trials or epidemiologic investigations under this specific announcement.
Browse more opportunities from the same category: Health
Next opportunity: Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
Previous opportunity: Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 719
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 719) also looked into and applied for these:
| Funding Opportunity |
|---|
| Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional) Apply for PAR 18 735 Funding Number: PAR 18 735 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional) Apply for PAR 18 736 Funding Number: PAR 18 736 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 18 737 Funding Number: PAR 18 737 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed) Apply for RFA RM 18 011 Funding Number: RFA RM 18 011 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed) Apply for RFA RM 18 006 Funding Number: RFA RM 18 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Apply for RFA AR 19 007 Funding Number: RFA AR 19 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) Apply for RFA AR 19 006 Funding Number: RFA AR 19 006 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed) Apply for RFA AI 18 010 Funding Number: RFA AI 18 010 Agency: National Institutes of Health Category: Health Funding Amount: $3,100,000 |
| Making Health care Safer in Ambulatory Care Settings and Long Term Care Facilities (R18) Apply for PA 18 750 Funding Number: PA 18 750 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Examining Diversity, Recruitment and Retention in Aging Research (R24 Clinical Trial Not Allowed) Apply for PAR 18 749 Funding Number: PAR 18 749 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01 Clinical Trial Optional) Apply for PA 18 753 Funding Number: PA 18 753 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Next-Generation Biologics for Sustained HIV Remission (R01 Clinical Trial Not Allowed) Apply for RFA AI 18 017 Funding Number: RFA AI 18 017 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R21 Clinical Trials Not Allowed) Apply for PA 18 754 Funding Number: PA 18 754 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 No Independent Clinical Trials) Apply for PAR 18 755 Funding Number: PAR 18 755 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Curricular or Training Activities in Skills Development (Admin Supp Clinical Trial Not Allowed) Apply for PA 18 759 Funding Number: PA 18 759 Agency: National Institutes of Health Category: Health Funding Amount: $80,000 |
| Development of Curricular or Training Activities in Laboratory Safety (Admin Supp Clinical Trial Not Allowed) Apply for PA 18 758 Funding Number: PA 18 758 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Curricular or Training Activities in Rigor and Transparency to Enhance Reproducibility (Admin Supp Clinical Trial Not Allowed) Apply for PA 18 756 Funding Number: PA 18 756 Agency: National Institutes of Health Category: Health Funding Amount: $80,000 |
| Administrative Supplements to NIGMS Predoctoral Training Grants for the Development of Activities to Prepare Trainees for Careers in the Biomedical Research Workforce (Admin Supp Clinical Trial Not Allowed) Apply for PA 18 757 Funding Number: PA 18 757 Agency: National Institutes of Health Category: Health Funding Amount: $80,000 |
| Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed) Apply for RFA HG 18 001 Funding Number: RFA HG 18 001 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed) Apply for RFA HG 18 003 Funding Number: RFA HG 18 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 719", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.